Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421877 | 1.00 | PTPN1 (0.62) | PTPN1CYP3A4TDP1HPGDPOLB | |
| SCHEMBL4646583 | 0.85 | TDP1 (0.75) | PTPN1CYP3A4TDP1HPGDKMT2A | |
| SCHEMBL2955343 | 0.83 | ALDH1A1 (0.56) | PTPN1CYP3A4HPGDALDH1A1 | |
| SCHEMBL12586702 | 0.79 | CYP3A4 (0.77) | PTPN1CYP3A4TDP1HPGDPOLB | |
| SCHEMBL10106588 | 0.79 | CYP3A4 (0.62) | PTPN1CYP3A4TDP1HPGDPOLB | |
| SCHEMBL658125 | 0.79 | PTPN1 (0.53) | PTPN1CYP3A4TDP1HPGDPOLB | |
| SCHEMBL31090180 | 0.79 | PTPN1 (0.53) | PTPN1CYP3A4TDP1HPGDPOLB | |
| Cyperin SCHEMBL31346631 | 0.78 | PTPN1 (1.00) | PTPN1CYP3A4TDP1HPGDPOLB | |
| SCHEMBL1402215 | 0.77 | CYP3A4 (0.60) | PTPN1CYP3A4TDP1MAPTMAPK1 | |
| SCHEMBL14511772 | 0.77 | TPMT (0.58) | PTPN1CYP3A4TDP1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4153555-B1 | PHOTOOXIDATION OF PHENOLIC COMPOUNDS | DSM IP ASSETS BV (NL) | 2024-01-31 | — | — | EP | disclosed |
| EP-4153555-A1 | PHOTOOXIDATION OF PHENOLIC COMPOUNDS | DSM IP Assets B.V. (NL) | 2023-03-29 | — | — | EP | disclosed |
| CN-115667201-A | Photooxidation of phenolic compounds | 帝斯曼知识产权资产管理有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021234080-A1 | PHOTOOXIDATION OF PHENOLIC COMPOUNDS | DSM IP ASSETS B.V. (NL) | 2021-11-25 | — | — | WO | disclosed |
| US-8722896-B2 | Prokineticin receptor antagonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-09 | — | — | US | disclosed |
| EP-1562589-B1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | PROKR2, PROKR1, GIPR | PTPN1 4163/4885CYP3A4 4337/4885TDP1 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.